5-decyl-1H-tetrazole | 149475-91-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-decyl-1H-tetrazole
• 英文别名: 5-decyl-2H-tetrazole
• CAS: 149475-91-2
• 化学式: C₁₁H₂₂N₄
• 分子量: 210.322
• InChiKey: VOXNMOCHRNJMIS-UHFFFAOYSA-N

物化性质

• 沸点：
  340.0±25.0 °C(Predicted)
• 密度：
  0.990±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  15
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  54.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-decyl-1H-tetrazole 、 Alpha-溴苯乙酸乙酯 在 三乙胺 作用下， 以 乙腈 为溶剂， 以34%的产率得到ethyl (1)-5-decyl-α-phenyl-2H-tetrazole-2-acetate
  参考文献：
  名称：

  Isoxazolyl-substituted alkyl amide ACAT inhibitors

  摘要：

  具有ACAT抑制活性的药用化合物的化学式为##STR1##其中n为0、1或2，对于X除了四唑，n=2时R.sub.2 =R.sub.3 =H；R.sub.1为苯基、取代苯基、萘基、取代萘基、杂环芳基或具有1至18个碳原子的碳氢基；R.sub.2和R.sub.3为氢、卤素、羟基、烷基、烯基、环烷基、苯基、取代苯基、杂芳基或形成螺环烷基；X为含有1至4个杂原子的杂单环5元环，所述杂原子为氮、氧或硫，以及它们的组合；R.sub.4为具有1至20个碳原子的碳氢基，同时描述了它们的制备方法。

  公开号：

  US05366987A1
• 作为产物：
  描述：

  N-十一烷基腈 在 叠氮基三甲基硅烷 作用下， 以 丙酮 为溶剂， 反应 0.25h， 以76%的产率得到5-decyl-1H-tetrazole
  参考文献：
  名称：

  连续流动从腈中合成5-取代的1 H-四唑：在缬沙坦合成中的应用

  摘要：

  描述了合成5-取代的1 H-四唑的有效连续流方法。该方法涉及聚合物负载的三有机锡叠氮化物与有机腈之间的反应。用聚苯乙烯负载的三有机锡醇盐和三甲基甲硅烷基叠氮化物原位生成的聚合物负载的有机锡叠氮化物被固定在填充床反应器中。这种方法简单，快速（耗时7.5至15分钟），并保证了产品中锡残留物的浓度低（<5 ppm）。该方法开发为芳基，杂芳基和烷基腈，并用于合成血管紧张素II受体拮抗剂缬沙坦。

  DOI：

  10.1021/acs.oprd.9b00526

文献信息

• [EN] HETERO BIARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS<br/>[FR] DERIVES HETERO BIARYLE INHIBITEURS DE LA METALLOPROTEASE MATRICIELLE
  申请人：WARNER LAMBERT CO

  公开号：WO2004014366A1

  公开（公告）日：2004-02-19

  This invention provides compounds defined by Formula I or a pharmaceutically acceptable salt thereof, wherein Rl, Q, S, T, U, V, and R2 are as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined in the specification, together with a' pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal a compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering to the patient a' compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides methods of treating diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency,,inflammatory bowel, disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically, acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides combinations, comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active, component as described in the specification.

  该发明提供了由式I定义或其药用盐组成的化合物，其中R1、Q、S、T、U、V和R2如规范中所定义。该发明还提供了包括式I的化合物或其药用盐以及药用载体、稀释剂或赋形剂的药物组合物，如规范中所定义。该发明还提供了在动物体内抑制MMP-13酶的方法，包括向动物体内给予式I的化合物或其药用盐。该发明还提供了治疗患有MMP-13酶介导疾病的患者的方法，包括向患者体内给予式I的化合物或其药用盐，单独或与药物组合使用。该发明还提供了治疗心脏病、多发性硬化症、骨关节炎和类风湿性关节炎、非骨关节炎或类风湿性关节炎的关节炎、心力衰竭、炎性肠病、心力衰竭、年龄相关性黄斑变性、慢性阻塞性肺病、哮喘、牙周疾病、牛皮癣、动脉粥样硬化和骨质疏松症的方法，包括向患者体内给予式I的化合物或其药用盐，单独或与药物组合使用。该发明还提供了组合物，包括式I的化合物或其药用盐，以及规范中描述的另一种药用活性成分。
• TETRAZOLE SILANE COMPOUND, METHOD FOR SYNTHESIZING SAID COMPOUND AND USE THEREOF
  申请人：SHIKOKU CHEMICALS CORPORATION

  公开号：US20200223875A1

  公开（公告）日：2020-07-16

  The objectives of the present invention are: to provide a novel tetrazole silane compound, a method for synthesizing the same, and a silane coupling agent containing the tetrazole silane compound as a component; and to provide a surface treatment solution using the tetrazole silane compound, a method for surface treatment, and a method for adhering two different materials. The tetrazole silane compound according to the present invention is a compound represented by chemical formula (I). (In formula (I), X, R, and n are respectively the same as defined in the specification.)

  本发明的目的是：提供一种新型四唑硅烷化合物、其合成方法和包含该四唑硅烷化合物作为组分的硅烷偶联剂；以及提供使用该四唑硅烷化合物的表面处理溶液、表面处理方法和粘接两种不同材料的方法。本发明的四唑硅烷化合物是由化学式（I）表示的化合物。（在式（I）中，X、R和n分别与规范中定义的相同。）
• Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity
  申请人：Wulff Birgitte Schjellerup

  公开号：US20100022446A1

  公开（公告）日：2010-01-28

  The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.

  本发明涉及一种新型肽化合物，其能有效调节一个或多个黑色素皮质素受体类型，并且涉及使用这些化合物进行治疗的方法，包括将这些化合物用于需要治疗的患者的治疗方法以及将这些化合物用于制造药物。本发明的化合物在治疗肥胖以及与肥胖相关的各种疾病或病症方面具有特别的兴趣。
• Pyrazolo-substituted alkyl amide acat inhibitors
  申请人：Warner-Lambert Company

  公开号：US05441975A1

  公开（公告）日：1995-08-15

  Pharmaceutically useful compounds having ACAT inhibitory activity of the formula ##STR1## wherein n is 0, 1, or 2, for X other than tetrazole and n=2 then R.sub.2 =R.sub.3 =H; R.sub.1 is phenyl, substituted phenyl, naphthyl, substituted naphthyl, a heteroaromatic group or a hydrocarbon group having from one to 18 carbon atoms; R.sub.2 and R.sub.3 are hydrogen, halo, hydroxy, alkyl, alkenyl, cycloalkyl, phenyl, substituted phenyl, a heteroaryl, or form a spiroalkyl group; X is a heteromonocyclic 5-membered ring containing one to four heteroatoms, said heteroatoms being nitrogen, oxygen or sulfur, and combination thereof; and R.sub.4 is a hydrocarbon group having from one to 20 carbon atoms are described as well as methods of their manufacture.

  具有ACAT抑制活性的药用化合物的化学式为##STR1## 其中n为0、1或2，对于X而言，除了四唑，当n=2时，R.sub.2=R.sub.3=H; R.sub.1为苯基、取代苯基、萘基、取代萘基、杂芳基或具有1至18个碳原子的碳氢基；R.sub.2和R.sub.3为氢、卤素、羟基、烷基、烯基、环烷基、苯基、取代苯基、杂芳基或形成螺环烷基；X为含有1至4个杂原子的杂单环5-成员环，所述杂原子为氮、氧或硫，以及它们的组合；R.sub.4为具有1至20个碳原子的碳氢基，同时描述了它们的制造方法。
• Tetrazole alkyl amide acat inhibitors
  申请人：Warner-Lambert Company

  公开号：US05646170A1

  公开（公告）日：1997-07-08

  Pharmaceutically useful compounds having ACAT inhibitory activity of the formula ##STR1## wherein n is 0, 1, or 2, for X other than tetrazole and n=2 then R.sub.2 .dbd.R.sub.3 .dbd.H; R.sub.1 is phenyl, substituted phenyl, naphthyl, substituted naphthyl, a heteroaromatic group or a hydrocarbon group having from one to 18 carbon atoms; R.sub.2 and R.sub.3 are hydrogen, halo, hydroxy, alkyl, alkenyl, cycloalkyl, phenyl, substituted phenyl, a heteroaryl, or form a spiroalkyl group; X is a heteromonocyclic 5-membered ring containing one to four heteroatoms, said heteroatoms being nitrogen, oxygen or sulfur, and combination thereof; and R.sub.4 is a hydrocarbon group having from one to 20 carbon atoms are described as well as methods of their manufacture.

  具有ACAT抑制活性的药用化合物的化学式为##STR1## 其中n为0，1或2，对于X而言，除了四唑和n=2时，R.sub.2.dbd.R.sub.3.dbd.H; R.sub.1是苯基，取代苯基，萘基，取代萘基，杂环芳基或具有1至18个碳原子的碳氢基；R.sub.2和R.sub.3是氢，卤素，羟基，烷基，烯基，环烷基，苯基，取代苯基，杂芳基或形成螺环烷基；X是一个杂单环五元环，含有1至4个杂原子，这些杂原子是氮，氧或硫，以及它们的组合；R.sub.4是具有1至20个碳原子的碳氢基。同时还描述了它们的制造方法。